OBJECTIVE： To evaluate therapeutic efficacy of Tongxinluo capsule combined with statins in the treatment of coronary heart disease （CHD） complicated with hypertension， and to provide evidence-based reference in clinic. METHODS： Retrieved from PubMed， Cochrane library， Embase， CNKI， VIP， Wanfang database and CBM， randomized controlled trials （RCTs） about Tongxinluo capsule combined with statins on basis of basic treatment （trial group） versus statins （control group） in the treatment of CHD complicated with hypertension were collected from database establishment to June 19， 2017. After data extraction of included literatures and quality evaluation with Cochrane 5.1.0 bias risk evaluation tool， Meta-analysis of total response rate， LDL-C level， systolic blood pressure and diastolic blood pressure were conducted by using Stata 14 software. RESULTS： A total of 9 RCTs were included， involving 714 patients. Results of Meta-analysis showed that total response rate [RR＝1.26，95％CI（1.16，1.36），P＜0.001]， the reduction of LDL-C [WMD＝－0.25，95％CI（－0.39，－0.12）， P＜0.001]， the reduction of systolic blood pressure [WMD＝－5.69，95％CI（－9.33，－2.06）， P＝0.002] and the reduction of diastolic blood pressure [WMD＝－2.14，95％CI（－3.31，－0.98）， P＜0.001] in trial group were significantly better than control group， with statistical significance. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Tongxinluo capsule combined with statins can significantly improve total response rate， reduce LDL-C， systolic blood pressure and diastolic blood pressure without increasing the occurrence of ADE.